Evolus, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This filing reports annual results; it does not provide a clear standalone Q4 financial results breakdown. Evolus is a performance beauty company whose revenue is generated entirely by Jeuveau, an aesthetic botulinum toxin product.
Financial performance
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net revenue | $148.6 million | $99.7 million |
| Gross profit / gross margin | $89.8 million / 60.4% | $78.7 million / 79.0% |
| Adjusted gross profit margin (non-GAAP) | 62.4% | 56.3% |
| Operating loss | $65.3 million | $44.4 million |
| Net loss | $74.4 million | $46.8 million |
| Operating cash flow | $(84.9) million | $(33.4) million |
| Cash and cash equivalents at year-end | $53.9 million | $146.3 million |
| Term loan, net of discounts and issuance costs | $71.9 million | $71.2 million |
- Revenue rose 49.1%, primarily on higher Jeuveau sales volumes. Product revenue was $146.6 million; Canadian distribution service revenue was $2.0 million.
- Gross margin fell year over year in part because FY2021 included a one-time $25.5 million Daewoong settlement receipt. Adjusted gross margin, which excludes that receipt and intangible amortization, improved; it is a company-defined non-GAAP measure.
- Operating expenses increased to $213.9 million from $144.1 million. SG&A rose 26.6% to $141.8 million, mainly from personnel and commercial activity; R&D increased to $4.7 million, principally reflecting the extra-strength clinical trial.
- Interest expense increased to $9.1 million from $1.4 million, mainly due to the Pharmakon loan. Net loss per share was $1.33, compared with $0.94.
- Year-end working capital was positive at $54.3 million; stockholders’ equity was $18.5 million. Inventory increased to $18.9 million from $1.8 million.
Material changes and business developments
- Jeuveau remained the company’s sole commercial product and revenue source. Great Britain launched in September 2022; Germany and Austria launched in February 2023. Australia received regulatory approval in January 2023.
- Cash used in operations increased to $84.9 million from $33.4 million. Cash declined by $92.3 million during 2022, compared with a $43.7 million increase in 2021, when financing included equity offerings and the Pharmakon loan.
- The company had $75.0 million principal outstanding under its Pharmakon term loan. A further $50.0 million tranche was available at Evolus’s option through December 31, 2023, subject to conditions; it had not been drawn as of March 8, 2023. The debt bears a floating rate and matures in December 2027.
- The $35.0 million cash settlement payment to Allergan and Medytox was completed with a final $5.0 million payment in February 2023. Medytox royalties shifted to a mid-single-digit percentage of Jeuveau net sales from September 17, 2022 through September 16, 2032. Evolus also owes founders a low-single-digit sales royalty through 2029.
Outlook, commentary and risks
- Management expects continued sales growth to depend on expanding the customer base and increasing purchases by existing customers. It provided no quantitative FY2023 revenue or earnings guidance in the supplied filing text.
- Management said current resources—including cash, expected operating cash generation and available loan capacity—should fund operations for at least 12 months from issuance of the financial statements. The filing also reports recurring losses and negative operating cash flows, which management expects to continue for at least the next 12 months; future funding may be needed.
- Management expects a dynamic macroeconomic environment in 2023, with elevated cost inflation potentially pressuring consumer discretionary spending on aesthetic procedures. Higher interest rates may increase borrowing costs.
- Key business risks include dependence on one product; competition, including newly approved Daxxify; self-pay demand sensitivity to economic conditions; reliance on Daewoong as sole manufacturer and on maintaining license exclusivity; Medytox settlement compliance and ongoing royalties; and regulatory, product-liability, intellectual-property and cybersecurity risks.
- The Daewoong license has minimum purchase or market-share requirements and an initial term expiring September 30, 2023, with renewal subject to performance conditions. Failure to meet requirements could jeopardize exclusivity.
- A securities class action and related derivative litigation remained unresolved. Management could not reasonably estimate a loss range. The company reported effective disclosure controls and effective management assessment of internal control over financial reporting; the auditor did not provide an ICFR attestation.
- Interim Phase II extra-strength trial results announced in January 2023 indicated median duration of at least 26 weeks. No severe or serious adverse events were observed in the interim safety results. The trial was expected to finish in the first half of 2023, with final results expected in the second half.
Most important facts for investors to verify
- Whether revenue growth continues to translate into improving margins and a path to lower operating losses and cash burn.
- Cash runway and financing needs, including the terms and availability of the undrawn $50.0 million loan tranche and exposure to floating interest rates.
- Jeuveau sales momentum, customer retention, pricing and promotional discounts, international launch progress, and whether purchase requirements preserve Daewoong exclusivity.
- The effect of continuing Medytox and founder royalties on gross margin, cash flows and customer pricing.
- Final extra-strength trial results and any subsequent regulatory submission or approval progress.
- Developments in the securities and derivative lawsuits, and any material changes in supply, regulatory or product-safety risks.